Skip Navigation

Annals of Oncology 2009 20(Supplement 4):iv73-iv75; doi:10.1093/annonc/mdp134
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stahel, R. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stahel, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

ESMO clinical recommendations

Malignant pleural mesothelioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

R. A. Stahel1, W. Weder2, E. Felip3 and On behalf of the ESMO Guidelines Working Group*

1 Clinic and Policlinic of Oncology
2 Department of Thoracic Surgery, University Hospital of Zürich, Zürich, Switzerland
3 Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain

* Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland; E-mail: clinicalrecommendations@esmo.org

The first 10% of the full text of this article appears below.


   incidence
 
Malignant pleural mesothelioma (MPM) is a rare tumor. The incidence is 1.25/100 000 in Great Britain and 1.1/100 000 in Germany. Within the next 20 years the incidence is estimated to double in many countries. Exposure to asbestos is a well-established etiological factor for MPM, with occupational exposure having been documented in 70%–80% of those affected.


   diagnosis
 
Patients typically present with . . . [Full Text of this Article]


   staging and risk assessment
 

   treatment
 
surgery
radiotherapy
chemotherapy

   response evaluation
 

   follow-up
 

   note
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?